USPTO serial 90904157
TEMPO-SEQ
Reviewed by CopyMark Law Group
Status 748
- Filing date
- Status date
- Registration date
- —
- Examiner
- LOOK, JEFFREY J
- Law office
- TMO LAW OFFICE 126
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with TEMPO-SEQ?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Leigh AUGUSTINE
Leigh AUGUSTINE EIP US LLPEIP US LLP, 5445 DTC PARKWAY, PH4GREENWOOD VILLAGE, CO 80111United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Assays and reagents for use in genetic research; Assays for research purposes; Assays for testing nucleic acid sequences, antigens, metabolites, bacteria, and viruses, other than for medical or veterinary use; Biochemical catalysts; Biochemical preparations for scientific purposes; Biochemical reagents commonly known as probes, for detecting and analyzing molecules in protein or nucleotide arrays; Biochemical reagents used for non-medical purposes; Biochemicals for in vitro and in vivo scientific use; Biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; Biochemicals, namely, polynucleotides for in vitro and in vivo scientific and research purposes; Biochemicals, namely, polypeptides for in vitro research use; Biochemicals, namely, precursors for in vitro genetic engineering use; Biological preparations for use in industry and science; Biological tissue, namely, a set of matched frozen and fixed human biological specimens derived from the division of one original specimen for use in scientific and medical research; Biomedical compounds, namely, peptide substrates used in analyzing and detecting certain toxins for clinical or medical laboratory use; Biomedical compounds, namely, peptide substrates used in analyzing and detecting certain toxins for laboratory or research use; Catalysts for chemical and biochemical processes; Chemical reagents for non-medical purposes; Chemical reagents for non-medical purposes, namely, for use in evaluating nucleic acid sequences, antigens, and metabolites; Chemical reagents, other than for medical or veterinary purpose; Chemical solutions and preparations consisting of pre-mixed reactants and reagents for scientific and research use in connection with amplification, analysis or labeling of nucleic acid; Chemical substances for analyses in laboratories, other than for medical or veterinary purposes; Chemical test kits for biological samples and biochemical preparations, for laboratory or research use; Chemicals for use in biotechnological product development; Chemicals for use in the biochemical and chemical industry; Chemicals for use in the purification of proteins for in vitro use; Chemicals, namely, buffer and standard solutions used in analytical chemistry; Diagnostic preparations for clinical or medical laboratory use; Diagnostic preparations for scientific or research use; Diagnostic preparations for scientific or research use other than for medical use; Diagnostic preparations for scientific use; Diagnostic preparations other than for medical or veterinary purposes; Diagnostic preparations used in science; Diagnostic preparations, other than for medical or veterinary purposes; Diagnostic reagents and preparations, except for medical or veterinary use; Diagnostic reagents for clinical or medical laboratory use; Diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; Diagnostic reagents for scientific or research use; Diagnostic reagents for scientific use; Enzyme preparations for use in the biotechnology, nucleic acid detection, agricultural, and toxicology industry; Enzyme substrates; Enzymes derived from biotechnological processes for use in industry; Enzymes for scientific and research purposes; Immunohistochemistry detection kits consisting of mouse secondary reagents, DAB chromogens, DAB buffers, peroxidase blocking reagent, and hematoxylin, for anatomic pathology purposes in the medical diagnostics industry; Laboratory chemicals, namely, an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use; Nucleic acid for laboratory use; Nucleic acid isolation and purification kit consisting primarily of reagents and magnetic beads for scientific research purposes; Nucleic acid sequences and chemical reagents for other than medical and veterinary purposes; Nucleotides for scientific and research use; Reagent kits comprising generic DNA circle, DNA primers, polymerase and buffers for use in biotechnology fields; Reagents for research purposes; Reagents for scientific and research use; Reagents for scientific or medical research use; Reagents for testing biological samples, and biochemical preparations, other than for medical or veterinary use; Reagents for use in scientific apparatus for chemical or biological analysis; Test particles for biodetection systems, biological analogues and microscopic carrier beads with chemically attached DNA fragments for use in testing the operation of equipment used for analyzing air for the presence of harmful biological substances; Testing kits containing peptide substrates used in analyzing and detecting certain toxins for clinical or medical laboratory use; Testing kits containing peptide substrates used in analyzing and detecting certain toxins for laboratory or research use; all of the aforementioned goods expressly excluding sulfur for industrial applications | ACTIVE | Aug 1, 2026 |
| 009 | Automated laboratory equipment mainly for cutting specimens; Computer hardware; Computer hardware for detecting labeled molecules and analyzing genetic data, aligning sequences, controlling laboratory equipment, bioinformatics, expression profiling, and metabolic pathways; Computer hardware with preinstalled software for detecting labeled molecules and analyzing genetic data, aligning sequences, controlling laboratory equipment, bioinformatics, expression profiling, and metabolic pathways; Diagnostic apparatus for testing food; Diagnostic apparatus for the detection of pathogens for laboratory or research use; Digital media, namely, CDs, DVDs featuring medical forms; Downloadable mobile applications for detecting labeled molecules and analyzing genetic data, aligning sequences, controlling laboratory equipment, bioinformatics, expression profiling, and metabolic pathways; Downloadable electronic data files featuring medical documents; Downloadable software for detecting labeled molecules and analyzing genetic data, aligning sequences, controlling laboratory equipment, bioinformatics, expression profiling, and metabolic pathways; DNA chips; DNA microarrays; Downloadable cloud-based software for detecting labeled molecules and analyzing genetic data, aligning sequences, controlling laboratory equipment, bioinformatics, expression profiling, and metabolic pathways; Downloadable computer software for scientific analysis of genetic sequences; Downloadable computer software for the structural and functional analysis of genomes; Downloadable computer software for detecting labeled molecules and analyzing genetic data, aligning sequences, controlling laboratory equipment, bioinformatics, expression profiling, and metabolic pathways; Downloadable computer software for detecting labeled molecules and analyzing genetic data, aligning sequences, controlling laboratory equipment, bioinformatics, expression profiling, and metabolic pathways and instructional user guides sold as a unit; Downloadable databases in the field of biotechnology, nucleic acid detection, agricultural, and toxicology; Downloadable scientific and medical data via the internet; Downloadable software for dosimetry purposes in the field of radiotherapy; Filters for blood and blood components for laboratory use; Flow cytometers and flow-based analyzers providing cell and particle analysis, detection, or counting for scientific, laboratory, and general research uses; Hand-operated laboratory tools for manipulating laboratory samples; Laboratory apparatus and instruments for extracting nucleic acids and proteins; Laboratory devices for detecting genetic sequences; Laboratory instrument for the detection of pathogens and toxins in a biological sample for research use; Laboratory robots; Medical laboratory research instruments for detecting the presence of nucleic acid sequences, antigens, gene expression, tissue structures, and radiation exposure; Non-medical imaging devices for nucleic acids and chemical labels; Research laboratory analyzers for measuring, testing and analyzing blood and other bodily fluids; Scanner for capturing images for analysis for use in the life science research field; Scientific apparatus and instruments, namely, fluid handling device used for disposable bioprocessing applications and parts and fittings therefor; Scientific instrumentation for measuring concentrations of chemicals in water; Scientific instrumentation for measuring the quantity of nucleic acids and antigens, gene expression, and radiation exposure; Scientific instruments, namely, electronic analyzers for measuring, testing and detecting pollutants; Scientific instruments, namely, electronic analyzers for testing and analyzing chemical and biological substances for the presence, absence, or quantity of nucleic acid sequences and antigens, gene expression, and radiation exposure; Scientific research specimen collection devices in the nature of bottles, tubes, swabs, syringes, and wipes for the collection of nasal mucus, respiratory droplets, saliva, blood, urine, and feces; Temperature controller for controlling temperature of medical instruments and containers for medical fluids; Testing sample collection equipment, namely, wipes and swabs for use in diagnostic testing, not for medical purposes | ACTIVE | Aug 1, 2026 |
| 042 | Agricultural testing for nucleic acid sequences and gene expression; Analysis of water quality; Biochemical research and analysis; Biochemical research and development; Biological research; Biological research and analysis; Biotechnology research; Blood analysis services; Chemical analysis; Chemical analysis services; Chemical research; Chemical research and analysis; Chemical research services; Chemical, biochemical, biological and bacteriological research and analysis; Clinical research in the field of evaluating the presence of nucleic acids, antigens, gene expression, tissue structures, and radiation exposure; Computer programming consultancy in the field of in the field of biotechnology, nucleic acid detection, agricultural, and toxicology; Computer programming and software design; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Custom design and development of chemical reagents and biochemical assays; Developing computer software; Developing customized software for others; Developing and updating computer software; Development of new technology for others in the field of biotechnology, nucleic acid detection, agricultural, and toxicology; Diagnostic services in the field of biotechnology, nucleic acid detection, agricultural, and toxicology; DNA analysis services for scientific research purposes; DNA analysis services to determine paternity; DNA screening for scientific research purposes; Dosimetry monitoring services; Genetic mapping for scientific purposes; Genetic testing for scientific research purposes; Genotyping services for research or analysis purposes; Laboratory research in the field of biotechnology, nucleic acid detection, agricultural, and toxicology; Medical laboratory services; Medical research services in the field of cancer; Medical research services; Monitoring of water quality; Monitoring of DNA, RNA, proteins, and viruses for scientific research purposes; Providing information in the field of plant genetics research resources; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing laboratory research services in the field of gene expression, namely, cancer biology; Providing medical research and scientific research information in the field of oncology via the Internet; Providing medical testing services and information in the field of cancer research and disease classification; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Providing reagent sample testing and diagnostic services for others in the fields of science and research related thereto; Providing scientific information in the field of cancer, inherited diseases, infectious disease, viral disease, Covid-19, influenza, respiratory syncytial virus, coronary artery disease risk, and schizophrenia risk; Providing a website for the electronic storage of nucleotide sequences, single-nucleotide polymorphisms, and sample information; Rental of application software; Rental of computer hardware; Rental of computer hardware and computer software; Rental of computer software; Rental of computer software and programs; Rental of computers; Rental of computers and software; Rental of laboratory apparatus and instruments; Rental of laboratory robots; Research services in the field of forensic science, namely, analysis, detection and isolation of biological substances in forensic samples; Research and development and consultation related thereto in the field of cancer, inherited diseases, infectious disease, viral disease, Covid-19, influenza, respiratory syncytial virus, coronary artery disease risk, and schizophrenia risk; Research and development in the field of cancer, inherited diseases, infectious disease, viral disease, Covid-19, influenza, respiratory syncytial virus, coronary artery disease risk, and schizophrenia risk; Research and development of technology in the field of cancer, inherited diseases, infectious disease, viral disease, Covid-19, influenza, respiratory syncytial virus, coronary artery disease risk, and schizophrenia risk; Scientific research consulting in the field of cancer, inherited diseases, infectious disease, viral disease, Covid-19, influenza, respiratory syncytial virus, coronary artery disease risk, and schizophrenia risk; Scientific research for medical purposes in the area of cancerous diseases; Scientific research for medical purposes in the field of cancer, inherited diseases, infectious disease, viral disease, Covid-19, influenza, respiratory syncytial virus, coronary artery disease risk, and schizophrenia risk; Scientific research in the field of genetics and genetic engineering; Scientific research in the field of cancer, inherited diseases, infectious disease, viral disease, Covid-19, influenza, respiratory syncytial virus, coronary artery disease risk, and schizophrenia risk; Scientific study and research in the field(s) of cancer, inherited diseases, infectious disease, viral disease, Covid-19, influenza, respiratory syncytial virus, coronary artery disease risk, and schizophrenia risk; Scientific and technological services, namely, detection of the presence of nucleic acids and antigens, and modifications thereof, gene expression, tissue structures, and radiation exposure in the field of cancer, inherited diseases, infectious disease, viral disease, Covid-19, influenza, respiratory syncytial virus, coronary artery disease risk, and schizophrenia risk; Software as a service (SAAS) services featuring software for detecting labeled molecules and analyzing genetic data, aligning sequences, controlling laboratory equipment, bioinformatics, expression profiling, and metabolic pathways; Software as a service (SAAS) services, namely, hosting software for use by others for use detecting labeled molecules and analyzing genetic data, aligning sequences, controlling laboratory equipment, bioinformatics, expression profiling, and metabolic pathways; Technology advisory services related to biotechnology, nucleic acid detection, agricultural, and toxicology; Testing of chemicals; Testing of filters; Testing, inspection or research on agriculture, livestock breeding or fisheries; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy; Toxicology services; Water analysis | ACTIVE | Aug 1, 2026 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BioSpyder Technologies, Inc.
- Other trademarks owned by BioSpyder Technologies, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 009
- Other trademarks in Class 042
- Similar marks named TEMPO-SEQ
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 30, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 14, 2026 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Sep 11, 2026 | IUAF | USE AMENDMENT FILED | — |
| Sep 11, 2026 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jul 21, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 21, 2026 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Jul 21, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Mar 11, 2026 | EXT5 | SOU EXTENSION 5 FILED | — |
| Mar 11, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 13, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 12, 2025 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Sep 12, 2025 | EXT4 | SOU EXTENSION 4 FILED | — |
| Sep 12, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 13, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 12, 2025 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Mar 12, 2025 | EXT3 | SOU EXTENSION 3 FILED | — |
| Mar 12, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 11, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 11, 2024 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Sep 11, 2024 | EXT2 | SOU EXTENSION 2 FILED | — |
| Sep 11, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 12, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 11, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 11, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 11, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 12, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 18, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 18, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 28, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 9, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 22, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 21, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 21, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 21, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 21, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 21, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 31, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 12, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 30, 2021 | NWAP | NEW APPLICATION ENTERED | — |